Leptomeningeal vascularity in Gadopiclenol Enhanced Pediatric Brain MRI.

Sergio Valencia, Harry Griffin, Maria C Cortes-Albornoz, Suely Fazio-Ferraciolli, Michael S Gee, Jad S Husseini, Fedel Machado-Rivas, Samuel Cartmell, Camilo Jaimes
{"title":"Leptomeningeal vascularity in Gadopiclenol Enhanced Pediatric Brain MRI.","authors":"Sergio Valencia, Harry Griffin, Maria C Cortes-Albornoz, Suely Fazio-Ferraciolli, Michael S Gee, Jad S Husseini, Fedel Machado-Rivas, Samuel Cartmell, Camilo Jaimes","doi":"10.3174/ajnr.A9020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Gadolinium-based contrast agents (GBCAs) are essential in pediatric neuroimaging, enabling visualization of pathology that disrupts the blood-brain barrier. Gadopiclenol is a new macrocyclic GBCA with higher T1 relaxivity, permitting a 50% dose reduction while maintaining diagnostic quality. However, it is unknown whether this higher relaxivity alters background extra-axial vascular enhancement. We hypothesized that gadopiclenol, despite its lower dose, would increase background enhancement on post-contrast pediatric brain MRI compared to gadoterate meglumine (Gd-DOTA).</p><p><strong>Materials and methods: </strong>In this retrospective observational study, 302 contrast-enhanced brain MRI studies in patients aged 2-18 years were reviewed: 151 with gadopiclenol (0.05 mmol/kg) and 151 with Gd-DOTA (0.1 mmol/kg). Post-contrast sequences included 3D T1 spin echo (SE), 3D T1 gradient echo (SPGR), 2D T1 turbo spin echo (TSE), and 2D FLAIR. Two neuroradiologists established binary enhancement categories based on sulcal enhancement thresholds (high vs. low). One reader assigned scores for all studies; a second reader evaluated a subset for interobserver agreement. Logistic regression assessed the association between contrast agent and high enhancement, adjusting for age, sex, anesthesia, and scanner field strength.</p><p><strong>Results: </strong>Gadopiclenol was independently associated with significantly greater odds of high extra-axial enhancement on all T1-weighted sequences: 3D T1 SE (OR = 10.2, p < 0.001), 3D T1 SPGR (OR = 10.7, p < 0.001), and 2D T1 TSE (OR = 14.0, p < 0.001). Anesthesia was also an independent predictor of high enhancement on 3D SE and SPGR. On 2D FLAIR, contrast agent had no effect; instead, younger age was associated with high enhancement (p = 0.022), with an age-anesthesia interaction suggesting attenuation of this effect under sedation. Interobserver agreement was moderate to substantial (κ = 0.530-0.632).</p><p><strong>Conclusions: </strong>Gadopiclenol increases background extra-axial enhancement on T1-weighted post-contrast sequences in pediatric brain MRI, likely reflecting its higher relaxivity. Radiologists should be aware of this effect to avoid misinterpretation as leptomeningeal pathology. Post-contrast FLAIR remains unaffected and continues to serve as a reliable sequence for detecting true meningeal disease.</p><p><strong>Abbreviations: </strong>GBCA= gadolinium-based contrast agent; SE= spin echo; SPGR= spoiled gradient echo; TSE= turbo spin echo.</p>","PeriodicalId":93863,"journal":{"name":"AJNR. American journal of neuroradiology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJNR. American journal of neuroradiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3174/ajnr.A9020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Gadolinium-based contrast agents (GBCAs) are essential in pediatric neuroimaging, enabling visualization of pathology that disrupts the blood-brain barrier. Gadopiclenol is a new macrocyclic GBCA with higher T1 relaxivity, permitting a 50% dose reduction while maintaining diagnostic quality. However, it is unknown whether this higher relaxivity alters background extra-axial vascular enhancement. We hypothesized that gadopiclenol, despite its lower dose, would increase background enhancement on post-contrast pediatric brain MRI compared to gadoterate meglumine (Gd-DOTA).

Materials and methods: In this retrospective observational study, 302 contrast-enhanced brain MRI studies in patients aged 2-18 years were reviewed: 151 with gadopiclenol (0.05 mmol/kg) and 151 with Gd-DOTA (0.1 mmol/kg). Post-contrast sequences included 3D T1 spin echo (SE), 3D T1 gradient echo (SPGR), 2D T1 turbo spin echo (TSE), and 2D FLAIR. Two neuroradiologists established binary enhancement categories based on sulcal enhancement thresholds (high vs. low). One reader assigned scores for all studies; a second reader evaluated a subset for interobserver agreement. Logistic regression assessed the association between contrast agent and high enhancement, adjusting for age, sex, anesthesia, and scanner field strength.

Results: Gadopiclenol was independently associated with significantly greater odds of high extra-axial enhancement on all T1-weighted sequences: 3D T1 SE (OR = 10.2, p < 0.001), 3D T1 SPGR (OR = 10.7, p < 0.001), and 2D T1 TSE (OR = 14.0, p < 0.001). Anesthesia was also an independent predictor of high enhancement on 3D SE and SPGR. On 2D FLAIR, contrast agent had no effect; instead, younger age was associated with high enhancement (p = 0.022), with an age-anesthesia interaction suggesting attenuation of this effect under sedation. Interobserver agreement was moderate to substantial (κ = 0.530-0.632).

Conclusions: Gadopiclenol increases background extra-axial enhancement on T1-weighted post-contrast sequences in pediatric brain MRI, likely reflecting its higher relaxivity. Radiologists should be aware of this effect to avoid misinterpretation as leptomeningeal pathology. Post-contrast FLAIR remains unaffected and continues to serve as a reliable sequence for detecting true meningeal disease.

Abbreviations: GBCA= gadolinium-based contrast agent; SE= spin echo; SPGR= spoiled gradient echo; TSE= turbo spin echo.

加多匹克诺增强儿童脑MRI的小脑膜血管。
背景和目的:钆基造影剂(gbca)在儿童神经影像学中是必不可少的,可以使破坏血脑屏障的病理可视化。加多克lenol是一种新的大环GBCA,具有更高的T1松弛性,允许50%的剂量减少,同时保持诊断质量。然而,尚不清楚这种较高的弛豫度是否会改变背景轴外血管增强。我们假设,与gadterate meglumine (Gd-DOTA)相比,尽管剂量较低,gadadopiclenol会增加儿童脑MRI造影术后的背景增强。材料和方法:在这项回顾性观察性研究中,回顾了302例2-18岁患者的对比增强脑MRI研究:151例加多二烯醇(0.05 mmol/kg)和151例Gd-DOTA (0.1 mmol/kg)。对比后序列包括3D T1自旋回波(SE)、3D T1梯度回波(SPGR)、2D T1涡轮自旋回波(TSE)和2D FLAIR。两位神经放射学家根据脑沟增强阈值(高与低)建立了二元增强分类。一位读者给所有的研究打分;第二个读者评估了观察者间协议的子集。逻辑回归评估对比剂和高增强之间的关系,调整年龄、性别、麻醉和扫描仪场强度。结果:加多比lenol与所有T1加权序列的高轴外增强的几率显著增加独立相关:3D T1 SE (OR = 10.2, p < 0.001), 3D T1 SPGR (OR = 10.7, p < 0.001)和2D T1 TSE (OR = 14.0, p < 0.001)。麻醉也是3D SE和SPGR高增强的独立预测因子。在2D FLAIR上,造影剂无影响;相反,更年轻的年龄与高增强相关(p = 0.022),年龄-麻醉相互作用表明镇静下这种作用减弱。观察者间一致性为中度至重度(κ = 0.530-0.632)。结论:加多匹lenol增加了儿童脑MRI t1加权对比后序列的背景轴外增强,可能反映了其更高的松弛性。放射科医生应该意识到这种影响,以避免误解为脑膜轻症。对比后FLAIR不受影响,继续作为检测真脑膜疾病的可靠序列。缩写:GBCA=钆基造影剂;SE=自旋回波;SPGR=破坏梯度回波;涡轮自旋回波。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信